- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
FDA: C. difficile-associated diarrhea may be associated with proton pump inhibitors
The use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), according to a recent FDA Drug Safety Communication.
The use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), according to a recent FDA Drug Safety Communication.
A diagnosis of CDAD should be considered for patients taking PPIs who develop diarrhea that does not improve. Very elderly individuals, patients with some chronic medical conditions, and people on broad-spectrum antibiotics are said to be at-risk for developing CDAD.
FDA is working with manufacturers to include information in the drug labels about the increased risk of CDAD with use of PPIs.
"This is another example of the importance of recognizing that with all medications we balance benefits against risks," Ruth Ann C. Opdycke, PharmD, MS, president, TPG Healthcare Consulting LLC, told Formulary. "And medications that are commonly available without a prescription such as the proton pump inhibitors are not an exception to this rule.
"The critical factor, which the FDA and healthcare providers are working on, is quickly educating both healthcare providers and consumers about newly identified adverse events," added Opdycke. "From a Pharmacy and Therapeutics Committee perspective, the key is to develop the next phase after the formulary decision-making process to focus on evaluating outcomes of prior decisions and medication utilization."
PPIs work by reducing the amount of acid in the stomach. Prescription PPIs are used to treat conditions such as gastroesophageal reflux disease (GERD), stomach and small-intestine ulcers, and inflammation of the esophagus. OTC PPIs are used to treat frequent heartburn. FDA also is reviewing the risk of CDAD in users of histamine H2 receptor blockers. H2 receptor blockers are used to treat conditions such as GERD, stomach and small-intestine ulcers, and heartburn.
C. difficile is a bacterium that can cause diarrhea that does not improve. Symptoms include watery stool, abdominal pain, and fever, and patients may go on to develop more serious intestinal conditions. The disease also can be spread in hospitals.
FDA recommended that patients should immediately contact their healthcare professional and seek care if they take PPIs and develop diarrhea that does not improve. Healthcare professionals are recommended to use the lowest dose and shortest duration of PPI therapy appropriate to the patient's condition being treated.
Both healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Read the MedWatch safety alert, including a link to the FDA Drug Safety Communication, at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm290838.htm.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
